Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

The law is intended to crack down on Chinese biotech companies, but it may become more difficult to pass next year.

Opinion: Low pay, high pressure, a troubling political landscape — it’s all leading to medical students electing not to ...

Klitzman joins today’s First Opinion Podcast along with Molly O’Neil Frank, the staff palliative care chaplain at Memorial ...

The Office for Civil Rights is not checking if health care providers who handle Americans’ sensitive data comply with health ...

President-elect Trump has nominated biotech investor Jim O’Neill for deputy secretary of the Health and Human Services ...

President-elect Trump has chosen Stanford University professor Jay Bhattacharya to lead the National Institutes of Health, ...

Health officials in British Columbia, Canada, have failed, for now, to confirm how a teenager there became infected with H5N1 ...

Marty Makary, a Johns Hopkins surgeon and outspoken critic of parts of the U.S. medical system, is Trump’s pick for FDA ...

LONDON — Policymakers and scientific groups need to specify guidelines for the burgeoning field that uses stem cells to mimic ...

New study finds that AI didn't help reduce radiologists' burnout, HHS called out for not auditing HIPAA compliance, and more.